Brian Fry's extensive business development experience as well as an established track record of helping client’s navigate complex Chemistry, Manufacturing and Controls in the ATMP space, as well as biologics and vaccines.
He spent nearly ten years with Charles River Laboratories Biologics Solutions division where he led two business development teams and helped countless clients with their contract testing and manufacturing needs.
Most recently at Charles River Laboratories, he led the Business Development team for the cell therapy CDMO division (formerly Cognate Bioservices) where he was part of the commercialization of an allogeneic therapy for the European market as well as an autologous therapy for the US.
Prior to joining Charles River, he spent nearly eight years working for a contract testing and aseptic fill and finish organization called Irvine Pharma (acquired by Nitto Denko) where he supported 20+ PAIs across a host of modalities.
BA in management from the California State University, Fullerton as well as an MBA from the Isenberg School of Management, UMass Amherst.